QLGN שווי כולל של נכסי החברה Qualigen Therapeutics Inc

The market trend for the total assets of Qualigen Therapeutics (QLGN), which reached 25.63, demonstrates a business foundation based on the implementation of FastPack systems and oncology research. The company is currently actively developing its R&D sector, creating targeted molecules against cancer and viruses. However, the strategic shift toward pharmaceuticals entails serious financial risks and a dependency on the success of new clinical trials.

Scaling diagnostic systems and developing oncology drugs at Qualigen Therapeutics (QLGN) requires significant resources, the volume of which is reverse-calculated via return on assets (ROA) to strip the balance sheet mass of one-off market distortions. This method measures total capital and liabilities, where stable dynamics confirm financial resilience, while sharp deviations in the structure of assets and resources signal critical risks.